These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12183151)

  • 1. Opportunities and obstacles in developing a vaccine for Entamoeba histolytica.
    Miller-Sims VC; Petri WA
    Curr Opin Immunol; 2002 Oct; 14(5):549-52. PubMed ID: 12183151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future for vaccine development against Entamoeba histolytica.
    Quach J; St-Pierre J; Chadee K
    Hum Vaccin Immunother; 2014; 10(6):1514-21. PubMed ID: 24504133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the C-Terminal Fragment of Entamoeba histolytica Gal/GalNAc Lectin Intermediate Subunit as a Vaccine Candidate against Amebic Liver Abscess.
    Min X; Feng M; Guan Y; Man S; Fu Y; Cheng X; Tachibana H
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004419. PubMed ID: 26824828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with the Entamoeba histolytica surface metalloprotease EhMSP-1 protects hamsters from amebic liver abscess.
    Roncolato EC; Teixeira JE; Barbosa JE; Zambelli Ramalho LN; Huston CD
    Infect Immun; 2015 Feb; 83(2):713-20. PubMed ID: 25452550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge.
    Ivory CP; Chadee K
    Infect Immun; 2007 Oct; 75(10):4917-22. PubMed ID: 17620349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a Gal-lectin subunit vaccine against experimental Entamoeba histolytica infection and colitis in baboons (Papio sp.).
    Abd Alla MD; Wolf R; White GL; Kosanke SD; Cary D; Verweij JJ; Zhang MJ; Ravdin JI
    Vaccine; 2012 Apr; 30(20):3068-75. PubMed ID: 22406457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress towards development of a vaccine for amebiasis.
    Stanley SL
    Clin Microbiol Rev; 1997 Oct; 10(4):637-49. PubMed ID: 9336666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host-pathogen interaction in amebiasis and progress in vaccine development.
    Huston CD; Petri WA
    Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):601-14. PubMed ID: 9832261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amoebiasis vaccine development: A snapshot on E. histolytica with emphasis on perspectives of Gal/GalNAc lectin.
    Singh RS; Walia AK; Kanwar JR; Kennedy JF
    Int J Biol Macromol; 2016 Oct; 91():258-68. PubMed ID: 27181579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an epitope on the Entamoeba histolytica 170-kD lectin conferring antibody-mediated protection against invasive amebiasis.
    Lotter H; Zhang T; Seydel KB; Stanley SL; Tannich E
    J Exp Med; 1997 May; 185(10):1793-801. PubMed ID: 9151705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of the recombinant serine rich Entamoeba histolytica protein (SREHP) amebiasis vaccine in the African green monkey.
    Stanley SL; Blanchard JL; Johnson N; Foster L; Kunz-Jenkins C; Zhang T; Tian K; Cogswell FB
    Vaccine; 1995 Jul; 13(10):947-51. PubMed ID: 7483769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entamoeba histolytica: from adherence to enteropathy.
    Ravdin JI
    J Infect Dis; 1989 Mar; 159(3):420-9. PubMed ID: 2536786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenicity, immunogenicity and vaccine efficacy of the galactose-specific adherence protein of Entamoeba histolytica.
    Ravdin JI; Shain DC; Kelsall BL
    Vaccine; 1993; 11(2):241-6. PubMed ID: 8438621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin.
    Houpt E; Barroso L; Lockhart L; Wright R; Cramer C; Lyerly D; Petri WA
    Vaccine; 2004 Jan; 22(5-6):611-7. PubMed ID: 14741152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence-blocking vaccine for amebiasis.
    Petri WA; Chaudhry O; Haque R; Houpt E
    Arch Med Res; 2006 Feb; 37(2):288-91. PubMed ID: 16380334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.
    Abhyankar MM; Noor Z; Tomai MA; Elvecrog J; Fox CB; Petri WA
    Vaccine; 2017 Feb; 35(6):916-922. PubMed ID: 28089548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospect for an Entamoeba histolytica Gal-lectin-based vaccine.
    Gaucher D; Chadee K
    Parasite Immunol; 2003 Feb; 25(2):55-8. PubMed ID: 12791100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection in a gerbil model of amebiasis by oral immunization with Salmonella expressing the galactose/N-acetyl D-galactosamine inhibitable lectin of Entamoeba histolytica.
    Mann BJ; Burkholder BV; Lockhart LA
    Vaccine; 1997; 15(6-7):659-63. PubMed ID: 9178467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and immunogenicity of a codon-optimized Entamoeba histolytica Gal-lectin-based DNA vaccine.
    Gaucher D; Chadee K
    Vaccine; 2002 Sep; 20(27-28):3244-53. PubMed ID: 12213393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the PE
    Martínez-Hernández SL; Becerra-González VM; Muñoz-Ortega MH; Loera-Muro VM; Ávila-Blanco ME; Medina-Rosales MN; Ventura-Juárez J
    J Immunol Res; 2021; 2021():6697900. PubMed ID: 33824880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.